Kudos to $IMMU's team overcoming skeptics + getting across the FDA's finish-line (no easy feat). Nevertheless, catalyst = achieved, so selling the news to reevaluate catalysts could be smart. Why? B/c comm'l success isn't a given in #biotech. #StocksToTrade #stocks #investing https://t.co/Wf5N228nNJ